

NEWS

FOR IMMEDIATE RELEASE

EDITORIAL CONTACT:

David W. Bertoni
TheraTorr Medical, Inc.
P: 978.921.2097
C: 617.803.4719
dwbertoni@comcast.net

THERATORR GREETES NEW YEAR WITH CAPITAL INFUSION

Medical device developer raises capital to advance its SensorCell™ technology

Somerville, MA – December 31, 2010 – TheraTorr Medical, Inc, a privately-held, metro-Boston medical device developer, received a capital infusion from a seed-round, private placement offering to advance its SensorCell™ technology to the next stage of development and initiate clinical validation. The company has surpassed the minimum for this seed round and will continue to accept investments until the projected closing date of June 30, 2011.

The company is developing a highly innovative specialty mattress for the treatment and prevention of pressure (decubitus) ulcers, commonly known as 'bed sores'. Pressure ulcers are a serious public health problem, adding billions to the cost of acute and long-term health care. TheraTorr is concentrating on the acute care market, where hospitals are under intense pressure to reduce the incidence of pressure ulcers.

TheraTorr's patent-pending design uses independent, air-charged SensorCells to support the patient's weight evenly and drastically reduce excess pressure on natural boney protrusions. Each bed has hundreds of independent, vertically-oriented SensorCells, versus the current therapeutic mattress design of 20 -25 horizontal air-pillows. Despite this advantage, it is anticipated that this novel mattress will be economically competitive with existing, less efficient, mattresses.

"We have been very pleased with the enthusiastic response from investors, once they recognize the important market need that this device can meet with minimal additional development" said Don Freeman, one of the company Directors.

About TheraTorr Medical, Inc.:

TheraTorr is a Boston metro medical device development company, specializing in the development and marketing of flotation therapy beds for the prevention and treatment of pressure ulcers. TheraTorr has developed a novel pressure-reducing, medical mattress that has the potential to prevent tissue breakdown, accelerate the healing of pressure ulcers, and improve patient comfort. This innovative therapeutic surface is based on proprietary platform technology, the SensorCell™.

For further information about TheraTorr, visit the company's Web site at www.TheraTorr.com.

###